Key Highlights

  • CuraScientific manufactures and distributes cannabis, CBD, kava, and kratom products under Brand names including JW Brands and Chad Enterprises.
  • The company filed a notification of late filing (NT 10-K) with the SEC in April 2024, after which its regular reporting trail goes quiet.
  • Aggregated data indicate trailing Revenue around $1.05 million against roughly 5.5 billion shares outstanding and a headcount reported near two.
  • CSTF shows a 0% one-day change in the last closing session, consistent with a nano-cap trading almost entirely on speculative screening rather than news.

CuraScientific Corp (OTC:CSTF) sits at the intersection of two of the market's riskiest corners: sub-penny over-the-counter stocks and the cannabis consumer-products business. Trading at a fraction of a cent with a Market Value in the low thousands of dollars in the last closing session, the company is a nano-cap whose story is defined less by any imminent catalyst than by its status as a delinquent SEC filer with a small but growing consumer-products operation.

Company and Latest Development

Based in Coachella, California, CuraScientific manufactures, distributes and sells cannabis, CBD, kava and kratom products under brand names including JW Brands and Chad Enterprises. The company was originally incorporated as Boon Industries and rebranded to CuraScientific Corp. in April 2023 following a series of transactions, including a Merger and license agreements.

SEC records show a cluster of filings through late 2023 and early 2024, including a notification of late filing (NT 10-K) in April 2024, after which the regular reporting trail goes quiet, a hallmark of a company that has fallen behind on its disclosure obligations.

What Is Driving Attention Around CSTF?

There is no verified, company-specific catalyst behind the current attention, and the snapshot shows a 0% one-day change. Interest in a name like CSTF generally comes from screening for cannabis-linked micro-caps rather than from fresh, confirmed news.

Aggregated data indicate revenue in the low seven figures on a trailing basis, with a very large percentage growth rate that reflects expansion off a tiny base rather than a proven, scalable business. Absent current filings, visibility into the company's real trajectory is limited.

Key Numbers and Company Position

The figures describe a nano-cap: a quoted price around a hundredth of a cent, a market Capitalization of only a few thousand dollars, and roughly 5.5 billion shares outstanding against a headcount reported near two.

Trailing revenue is described as around $1.05 million, a small absolute figure despite the outsized growth percentage. These aggregator values are unverified, and the absence of up-to-date SEC filings means investors cannot rely on audited, current financials.

What Could Come Next?

The clearest constructive development would be a return to timely SEC or OTC Markets reporting, which would restore basic transparency. Beyond that, expansion of product distribution, new brand partnerships, or financing could matter, though cannabis and kratom businesses face financing constraints and shifting regulation.

Nothing verified is pending, so any near-term move is more likely to reflect speculative trading than a disclosed milestone. Watchers would look to new filings for evidence of operational progress.

Risks to Watch

The risks are substantial. Delinquent filing status limits transparency and can lead to trading restrictions or reputational discounts. The enormous share count creates ongoing dilution risk, and sub-penny pricing brings extreme volatility, wide spreads and a real possibility of total loss.

Cannabis, CBD and kratom products face an uncertain and patchwork regulatory environment across jurisdictions. Liquidity is thin, and reliable, current financial information is difficult to obtain.

Real Revenue, Missing Disclosure

CuraScientific Corp is a speculative cannabis consumer-products nano-cap whose most notable feature is what is missing: current, reliable financial disclosure. The company has real brands and modest revenue, but its delinquent-filer status, billions of shares outstanding and sub-penny price dominate the risk picture.

With no verified near-term catalyst, CSTF trades largely on speculation. Investors may be watching for a resumption of regular filings and any concrete operational updates, while treating the stock's ultra-low price and thin liquidity as the central risks rather than incidental details.